warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
COG AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Brief Description  
Primary Objective To compare the event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab (AMG 479).
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Soft Tissue
Status  
OPEN
Start Date  
01/25/2017
IRB Number  
00012270
Principal Investigator  
Kaplan, Joel Adam
Contact Name  
Sceria Jenkins

For More Information, Contact  Sceria  , Jenkins
Phone:  980-442-2323 Fax:    
Email:  sceria.jenkins@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close